Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals - authors' reply

Affiliations

Comment

V Saxena et al. Aliment Pharmacol Ther. 2014 Jun.

. 2014 Jun;39(12):1428.

doi: 10.1111/apt.12775.

¹ University of California San Francisco, San Francisco, CA, USA. norah.terrault@ucsf.edu.

No abstract available

Comment on

Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.
Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, Shvachko VA, Pauly MP, Chua J, Monto A, Terrault NA. Saxena V, et al. Aliment Pharmacol Ther. 2014 May;39(10):1213-24. doi: 10.1111/apt.12718. Epub 2014 Mar 24. Aliment Pharmacol Ther. 2014. PMID: 24654657 Free PMC article.
Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals.
Wong VW, Liu CJ. Wong VW, et al. Aliment Pharmacol Ther. 2014 Jun;39(12):1427-8. doi: 10.1111/apt.12745. Aliment Pharmacol Ther. 2014. PMID: 24849149 No abstract available.